Mark Auerbach


Mr. Auerbach has been a director since 2010. From 2014 until 2016, he was non-executive Chairman, and from 2013 until 2016, he was audit Chairman of RCS Capital Corporation, a publicly traded financial services company. Mr. Auerbach was formerly the Chairman of Neuro-Hitech, an early-stage pharmaceutical company. He was also lead independent director and Chairman of the audit committee of Optimer Pharmaceuticals, a public company, until its acquisition by Cubist Pharmaceuticals. Over the past 20 years, Mr. Auerbach has served as a director for several other companies, including Par Pharmaceutical Companies, a publicly traded manufacturer and marketer of generic pharmaceuticals and the parent of Par Pharmaceutical. He received a BS in Accounting from Rider University.

Financial Expert